Avita Medical shares are trading higher after B of A Securities maintained a Buy rating on the stock and raised its price target from $18 to $27.
Portfolio Pulse from Benzinga Newsdesk
Avita Medical's stock is trading higher after Bank of America Securities maintained a Buy rating on the stock and increased its price target from $18 to $27.
July 28, 2023 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Avita Medical's stock, listed as RCEL, is expected to trade higher due to Bank of America Securities' maintained Buy rating and increased price target.
Bank of America Securities' maintained Buy rating and increased price target for Avita Medical indicates a positive outlook for the company's stock. This is likely to attract investors, leading to an increase in the stock's trading price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100